Last mentioned: Feb 26, 2026
Anticipated Filing
Expected regulatory submission for WVE-N531 in Duchenne muscular dystrophy.
FY 2025 Earnings
Wave and Collegium release full-year financial results and 2026 guidance.
RNA Editing Milestone
WVE-006 demonstrates successful RNA editing in AATD patients.
DMD Breakthrough
Wave reports industry-leading dystrophin expression for WVE-N531.
The Q4 2025 earnings cycle for mid-cap healthcare highlights a strategic shift from clinical validation to commercial execution across gene editing, radiopharmaceuticals, and digital health. While platform innovators like Intellia and Kymera advance toward pivotal milestones, commercial leaders like Lantheus and Vericel are demonstrating the durability of high-barrier therapeutic markets.
Wave Life Sciences and Collegium Pharmaceutical released their Q4 and full-year 2025 results, highlighting a pivotal year for RNA editing and specialty pain management. Wave's transition toward a commercial-stage biotech is accelerated by its GSK partnership and landmark clinical data in Alpha-1 antitrypsin deficiency.